Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Addex Therapeutics Ltd

Market Cap 6.42M 7.94M 6.94M 5.99M 11.24M 750M 11.32M 76.24M 29.66M 369M 29.8M 29.16M 1.28B P/E 2024
0.8x
P/E 2025 -0.88x
Enterprise Value 4.81M 5.95M 5.2M 4.49M 8.43M 563M 8.49M 57.18M 22.25M 277M 22.35M 21.87M 961M EV / Sales 2024
5.67x
EV / Sales 2025 28.1x
Free-Float
43.94%
Yield 2024 *
-
Yield 2025 -
1 day-5.65%
1 week+5.85%
Current month-5.65%
1 month-3.56%
3 months+24.00%
6 months-22.50%
Current year-21.66%
1 week 0.04
Extreme 0.041
0.05
1 month 0.04
Extreme 0.041
0.05
Current year 0.03
Extreme 0.0336
0.06
1 year 0.03
Extreme 0.0336
0.08
3 years 0.03
Extreme 0.0336
0.26
5 years 0.03
Extreme 0.0336
1.63
10 years 0.03
Extreme 0.0336
4
Manager TitleAgeSince
Chief Executive Officer 58 2013-05-31
Director of Finance/CFO 40 2017-05-31
Chief Tech/Sci/R&D Officer 69 2016-11-27
Director TitleAgeSince
Chairman 77 -
Director/Board Member 58 2014-12-31
Director/Board Member 81 2010-05-11
Date Insider Type Main position Quantity % Market Cap.
03-17Other

Director

1,638,639 0.7494%
03-17Other

Founder

20,218,775 9.2469%
03-17Other

Chairman

3,009,585 1.3764%
Change 5-day change 1-year change 3-year change Capi.($)
-5.65%+5.85%-27.67%-60.18% 8.42M
+0.34%+2.06%-10.67%-5.26% 43.13B
+1.73%+7.76%+318.08%+543.17% 34.65B
+0.61%+2.77%+10.00%+46.44% 30.03B
+0.02%-7.52%+8.45%-21.52% 28B
-1.06%-2.60%+9.08%+21.51% 24.45B
-1.23%+4.56% - - 14.34B
-0.99%-2.50%+47.29%+106.70% 13.14B
+1.54%-0.94%+6.69%+8.40% 12.53B
+2.39%+3.57%+102.86%+83.89% 12.25B
Average -0.38%+1.81%+51.57%+80.35% 21.25B
Weighted average by Cap. +0.16%+1.19%+67.03%+113.26%

Financials

2024 2025
Net sales 410K 507K 443K 383K 718K 47.94M 724K 4.87M 1.9M 23.57M 1.9M 1.86M 81.89M 173K 214K 187K 161K 303K 20.21M 305K 2.05M 799K 9.94M 803K 786K 34.52M
Net income 7.06M 8.73M 7.63M 6.59M 12.36M 825M 12.45M 83.85M 32.62M 406M 32.78M 32.06M 1.41B -6.73M -8.32M -7.27M -6.28M -11.79M -787M -11.88M -79.95M -31.11M -387M -31.25M -30.58M -1.34B
Net Debt -3.3M -4.08M -3.57M -3.08M -5.78M -386M -5.82M -39.21M -15.26M -190M -15.33M -15M -659M -1.6M -1.98M -1.73M -1.5M -2.81M -188M -2.83M -19.06M -7.42M -92.2M -7.45M -7.29M -320M
Logo Addex Therapeutics Ltd
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
Employees
3
Date Price Change Volume
26-06-22 0.0434 CHF -5.65% 181,002
26-06-19 0.0460 CHF +3.60% 7,967
26-06-18 0.0444 CHF +1.37% 72,001
26-06-17 0.0438 CHF +0.46% 266,435
26-06-16 0.0436 CHF -4.80% 593,144
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ADXN Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!